Mon, Nov 24, 2014, 5:33 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Retractable Technologies, Inc. Message Board

repo_105 14 posts  |  Last Activity: Nov 14, 2014 11:03 PM Member since: Apr 5, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • " On June 17, 2014, we received notice of substantial equivalence from the Food and Drug Administration for the EasyPoint ™ needle. The EasyPoint ™ is a retractable needle that can be used with Luer lock syringes, Luer slip syringes, and prefill syringes to give injections. The EasyPoint ™ needle can also be used to aspirate fluids and obtain blood collection. We have not yet begun manufacturing the EasyPoint ™ needle"
    After reading the 510k summary on the FDA website, this device can attach to any syringe and enable it to retract the needle, whether it's a standard syringe or a prefilled syringe. IMHO, this looks very promising.

  • On a fundamental note, RVP recorded its most profitable quarter since the 4th qtr.of 2009. Back then they had the big contract from the government during the H1N1 outbreak.

    Hopefully, this is a sign of better things to come.................

  • Becton Must Pony Up $340M In Syringe Antitrust Suit

    Share us on:     By Michael Lipkin
    Law360, San Diego (November 10, 2014, 9:49 PM ET) -- A Texas federal judge on Monday granted Retractable Technologies Inc.’s bid to recover profits from Becton Dickinson & Co. for falsely claiming its safety syringes had the “world’s sharpest needle,” but ruled that the $340 million RTI will get from trebling its jury win is enough.2) RVP will also receive 50% of the attorney's fees to be determined from the $36,491.587 amount RVP requested. 3) RVP granted injunctive relief in-part and denied-in-part by no later than January 15, 2015. BDX must comply to five sets of orders, to notify their customers of wrongdoing.

    The court is of the opinion that the parties would benefit from further mediation. Therefore, the court ORDERS the parties to attend mediation before Judge T. John Ward with representatives with full authority to settle by January 15, 2015

    To sum it up BDX is on the hook for at least 350-360 million dollars.

    IMHO, BDX should purchase RVP and move on. RVP is now in the drivers seat............

  • The conference call was delayed 20 minutes, not because of technical difficulties, but because UNIS had to adjust their revenue down by $2 million dollars for the quarter.

    UNIS also pushed back their cash flow breakeven from 2016-2017 to 2018-2020. From last year's 2013 4th quarter conference call:

    "Now so in terms of -- the cash flow from the devices are not that relevant from the point of view that -- because we're not dependent on the device sales to actually cover our burn rate. But the device sales, again, I'd go back to what I said earlier is, we're looking 3, 4 years out of operating margins north of 40%."

    IMHO, UNIS mgmt. has a credibility issue. Not long or short UNIS.

    Where's Cramer when you need him?

  • BDX reports their 4th quarter results on Tuesday Nov 4th, and will release their 2014 at the end of November.

    Last year this was their 1st paragraph, in the legal proceedings section:
    Item 3. Legal Proceedings.

    "Given the uncertain nature of litigation generally, BD is not able in all cases to estimate the amount or range of loss that could result from an unfavorable outcome of the litigation to which BD is a party. In accordance with U.S. generally accepted accounting principles, BD establishes accruals to the extent probable future losses are estimable (in the case of environmental matters, without considering possible third-party recoveries). In view of the uncertainties discussed below, BD could incur charges in excess of any currently established accruals and, to the extent available, excess liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on BD’s consolidated results of operations and consolidated cash flows."

    Curious how it will read this year. IMHO, with the JMOL recently denied by the court and 100s of millions on the line for BDX to pay to RVP, BDX will open a can of worms if they don't settle or acquire RVP.

  • It's been 30 days since the denial of the JMOL for BDX, and 13 months since the jury verdict in favor of RVP.
    Will judge Davis give a final judgment on the jury verdict tomorrow?

  • IMHO,HHS should make sure that most Americans get the flu shot this year, to make sure that people don't panic when they come down with symptoms of fever and fatigue, and rush to the emergency rooms due to unfounded fears.

  • Back in 2005 there was an article entitled "Stick It To'em " by Patricia B. Gray that quoted Shaw never wanted the money. (Every investor should google this article and read it) Here is the quote:
    "Last year Retractable Technologies' revenue for the first nine months was $16 million, with a net profit of $55 million, reflecting the one-time gain from the settlements. Retractable lost money on operations for the period. Becton Dickinson posted 2004 revenues of nearly $5 billion, with a net profit of $467 million--down 14% from 2003, in part because of its settlement with Shaw. "I never wanted the money," Shaw says. "I just want to get into the hospitals. Doctors and nurses are dying."

    IMHO, RVP has great products but lousy management. Shaw should keep his word and start distributing it to his minority shareholders.

  • IMHO,the Ebola virus is a wakeup call for every hospital and clinic to provide safety syringes to their healthcare workers.
    The Needle Safety and Prevention Act was passed back in 2000, and unfortunately it hasn't been enforced over the past 14 years. It's a joke what hospitals consider what a safety needle actually is. RVPs victory verdict against BDX is the cake, but RVP'S safety syringe products are the icing.
    The governments of all countries better wake up and start providing safety products and procedures for all their healthcare workers.

  • Reply to

    New Patent Applications

    by tesiman Oct 8, 2014 3:36 PM
    repo_105 repo_105 Oct 8, 2014 11:22 PM Flag

    RVPs Easypoint needle looks the most promising and could be a game changer. From the Fly On The Wall Website: June 24th.
    15:37 EDT RVP Retractable Technologies gets FDA 510k clearance for Easypoint Needle
    The Easypoint Needle from Retractable Technologies was determined to be "Substantially Equivalent" by the FDA on June 17, according to a 510(k) premarket notification posted to the regulator's website. Reference Link :

  • "Vincent A. Forlenza - Chairman, Chief Executive Officer and President
    So we're not a believer in scale for scale's sake. Our strategy is really focused on creating complete solutions for the customer and driving value that way. We think that, that aligns much more with the basic customer needs and how buying processes are evolving. So we really think strategically around each one of these business units and how they can build out solutions. And if you look at how we might work across business units to create more complete solutions, it's a second element of our strategy that we are developing. All of that lines up with -- more with our plug-in M&A strategy. And so that's really the core of what we're trying to do. And certainly, there are people who are playing this out differently in terms of just more and more breadth, but that's not what we're attempting."

  • BD Stuck With $114M Antitrust Verdict After New Trial Denied

    Share us on:     By Jeff Sistrunk
    Law360, Los Angeles (September 30, 2014, 10:42 PM ET) -- A Texas federal judge on Tuesday rejected Becton Dickinson & Co.'s bid to ax a $113.5 million damages verdict in favor of Retractable Technologies Inc. and send the syringe market monopolization case back to a jury for a new trial, ruling that evidence presented during trial supported the jury's findings.

    U.S. District Judge Leonard Davis denied BD's renewed motion for judgment as a matter of law, new trial or remittitur.

    Score one for the little guy................................................

  • Full Fed. Circ. Won't Eye 'Mandate Rule' In Becton IP Case

    Share us on:     By Ryan Davis
    Law360, New York (September 19, 2014, 8:41 PM ET) --" The full Federal Circuit decided Friday not to review the so-called mandate rule requiring lower courts to strictly comply with appeals court decisions, rejecting Becton Dickinson and Co.'s argument that the rule was misapplied when the court refused to reduce a $5 million patent verdict against it.
    Becton was seeking en banc review of a July panel decision that it must pay all of the $5 million award to Retractable Technologies Inc., even though the finding that it infringed was partly reversed by the Federal Circuit three years ago."

    This finally clears up the patent infringement case, and will allow RVP to keep the original $5 million awarded by Judge Davis to RVP .

    IMHO, This event will now free up Judge Davis to make a judgement on the anti-trust case.. It should be coming shortly.

  • Didn't Judge Davis say back in January:"Court addressed the parties and will take under advisement and get a ruling as quickly as it can."

    Good thing I didn't hold my breadth......

4.50+0.460(+11.39%)Nov 24 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.